Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.3852W HIGH $3.47
Volume
2.42 M
Value Traded
6.72 M
Short % Float
9.44%
0%Week
-9.16%1 Month
-26.92%3 Month
+20.63%6 Month
-54.38%5 Year
-77.88%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
459.48 M
EPS (TTM)
-0.03
P/E Ratio
-
Ent. Value
403.21 M
Total Shares
201.55 M
Float Shares
190.68 M
Insiders
5.38%
Institutions
76.01%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CERS Catalyst Timeline
Dated clinical, regulatory and corporate events for Cerus Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cerus Corporation
1Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Event history 1
Past FDA Catalysts and PDUFA Decisions
How CERS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D28 / 100
Pipeline Score
$69M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
0.2x
rNPV / MCap
Top 73%
Micro Cap(rank 481 of 658)
Percentile Rank
Cerus Corporation faces pipeline headwinds (28/100), with $173M risk-adjusted pipeline value, led by INTERCEPT treated platelets in Healthy (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| INTERCEPT treated platelets Monoclonal antibodyCompletedNCT02310412 | Healthy | Phase 2 | COMPLETED | 51 | Sep 1, 2015 |
Clinical Trial Results
Readouts, endpoints and source filings for every CERS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| INTERCEPT RBC system | RBC transfusion for complex cardiac surgery patients | Phase 3 | 2024-10-16 | positive topline results for the BARDA-funded ReCePI study, demonstrating non-inferiority for INTERCEPT RBCs compared to conventional RBCs when transfused to complex cardiac surgery patientsRead More | Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe Company to Host Conference Call and Webcast on WednesdayRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Jensen ChrystalOfficer (Chief Legal Officer) | Sell | -30,000 936,657 held | $2.98 | 08/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CERS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 0.1 % | 18.67 M | 6.40 M | -36.1% ( -3.61 M) |
CERS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CERS ranks across every disease it competes in
Competitive Position is a premium feature
See how CERS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCERS News
CERS▼ -25.6%on this news
Cerus Corporation Announces Second Quarter 2026 Financial Results
Cerus Corporation reported its financial results for Q2 2026, highlighting significant advancements in patient access to safer blood components globally. CEO Vivek Jayaraman emphasized the success of the INTERCEPT Fibrinogen Complex franchise in the U.S. The company continues to focus on enhancing its product offerings and expanding its market reach.
Read more →CERSCerus Corporation to Release Second Quarter 2026 Financial Results on July 30, 2026
Cerus Corporation has announced the release of its second quarter 2026 financial results, scheduled for July 30, 2026, after market close. Following the release, the company will host a conference call and webcast at 4:30 PM ET to discuss the results and provide insights into its business outlook. This event reflects the company's commitment to investor communication.
Read more →CERSCerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress
Cerus Corporation will present new evidence and innovations related to the INTERCEPT Blood System at the 39th International ISBT Congress. The event will highlight the company's global experience in blood safety and pathogen reduction technologies. Details on specific findings or innovations to be showcased were not provided.
Read more →CERSCerus Corporation Closes New Debt Facility of Up to $110 Million
Cerus Corporation has successfully closed a new debt facility that allows for borrowing up to $110 million. This financial move is aimed at strengthening the company's capital structure. Further details on the terms of the facility and its intended use were not disclosed in the announcement.
Read more →CERS▲ +5.7%on this news· ran to +42% by day 1
Cerus Corporation Announces First Quarter 2026 Financial Results
Cerus Corporation reported a strong start to 2026, with first-quarter revenues of $59.9 million, marking a 23% increase from the previous year. The company raised its product revenue guidance for the year, driven by heightened demand for its INTERCEPT Fibrinogen Complex. Despite a net loss of $1.6 million, Cerus anticipates significant regulatory and clinical milestones ahead.
Read more →CERSCerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System
Cerus Corporation has announced a four-year supply agreement with the French Blood Establishment for the INTERCEPT Blood System, which includes the new INT200 illumination device. This partnership aims to enhance blood safety and patient care. The INTERCEPT system has been in use in France since 2006 and is crucial for maintaining safe blood supplies during outbreaks. However, Cerus faces several commercialization and regulatory risks.
Read more →CERSCerus Corporation to Release First Quarter 2026 Financial Results on April 30, 2026
Cerus Corporation has announced the release date for its first quarter 2026 financial results, which is set for April 30, 2026. This announcement is part of the company's regular financial reporting schedule. Further details regarding the financial performance will be disclosed at that time.
Read more →CERS▲ +6.5%on this news
Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer
Cerus Corporation has announced the promotion of Vivek Jayaraman to President and CEO, effective July 1, 2026. This transition follows a thorough succession planning process and aims to prepare the company for its next phase of growth. Jayaraman has been with Cerus since 2016 and has significantly contributed to its revenue growth. William 'Obi' Greenman will take on the role of Executive Chairman.
Read more →CERS▼ -15.8%on this news
Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results
Cerus Corporation reported a total revenue of $233.8 million for 2025, marking a 16% increase from the previous year. The company achieved record product revenue of $206.1 million and narrowed its net loss. Despite challenges such as increased operating expenses and a slight decline in gross margin, Cerus remains optimistic about future growth, projecting a 9% to 11% increase in product revenue for 2026.
Read more →CERS▼ -5.9%on this news
Cerus Corporation to Participate in the TD Cowen 46th Annual Health Care Conference
Cerus Corporation will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026. The event will feature a live webcast accessible via the company's Investor Relations page. Cerus is focused on safeguarding the blood supply and has developed the INTERCEPT Blood System, which is approved in various regions.
Read more →CERSCerus Corporation to Release Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026
Cerus Corporation announced that it will release its fourth quarter and full-year 2025 financial results on March 2, 2026. Following the release, a conference call and webcast will be held at 4:30 P.M. ET to discuss the results and provide a business overview. The company is dedicated to ensuring the safety of the blood supply through its innovative technologies.
Read more →CERSDRK Blood Donation Service Baden-Württemberg – Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus’ INTERCEPT™ Blood System in Routine Clinical Practice
Cerus Corporation has announced the launch of the INITIATE study in collaboration with the German Red Cross Blood Donation Service Baden-Württemberg – Hessen. This multicenter, non-interventional study will evaluate the safety and integration of pathogen-inactivated platelet concentrates using the INTERCEPT Blood System in clinical practice. The study aims to enhance blood safety and ensure a reliable supply of platelets.
Read more →CERS▲ +10.2%on this news· ran to +33% by day 3
Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook
Cerus Corporation announced its preliminary product revenue for Q4 and full-year 2025, reporting $206.1 million, a 14% increase over 2024. For 2026, Cerus expects product revenue to rise to between $224 million and $228 million, reflecting 9%-11% growth. The company has assisted blood centers globally in producing approximately 3 million INTERCEPT treated blood component doses. Looking ahead, multiple development milestones are anticipated, including a PMA application submission for INT200 in mid-2026.
Read more →CERSCerus Corporation Announces Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance
Cerus Corporation announced significant financial results for the third quarter of 2025, reporting a total revenue of $60.2 million and a record product revenue of $52.7 million. The company raised its full-year product revenue guidance to between $202 million and $204 million, indicating strong commercial growth driven by the INTERCEPT Blood System. Despite the positive results, Cerus faced challenges with rising operating expenses and a decrease in product gross margin. The company also completed enrollment for its pivotal Phase 3 RedeS trial and anticipates results in late 2026.
Read more →CERSCerus Corporation Announces Second Quarter 2025 Financial Results
Cerus Corporation reported its financial results for Q2 2025, highlighting a total revenue of $60.1 million and a record product revenue of $52.4 million, marking a 16% increase from the previous year. The company raised its full-year product revenue guidance to between $200 million and $203 million, reflecting confidence in ongoing growth, particularly in the INTERCEPT product line. Additionally, Cerus achieved positive non-GAAP adjusted EBITDA of $0.9 million, despite reporting a net loss of $5.7 million for the quarter, attributed to rising operational costs.
Read more →CERSCerus Corporation Announces First Quarter 2025 Financial Results
Cerus Corporation reported a strong start to 2025 with first quarter product revenue of $43.2 million, marking a 13% increase year-over-year. The company reiterated its full-year revenue guidance of $194-$200 million and noted a positive gross margin and reduced net loss compared to the previous year. Key achievements included the CE Mark approval for the INT200 device and increased adoption of the INTERCEPT Fibrinogen Complex, contributing to the optimistic financial outlook.
Read more →CERSCerus Corporation Announces Full-Year and Fourth Quarter 2024 Financial Results
Cerus Corporation reported strong financial results for both the full year and fourth quarter of 2024, with product revenues increasing by 15% and 9% respectively. The company achieved positive operating cash flows for the fourth consecutive quarter and outperformed its adjusted EBITDA targets. However, government contract revenue declined significantly, and operating expenses rose for the fourth quarter. Cerus reaffirms its 2025 product revenue guidance, positioning itself for continued growth in blood safety technology.
Read more →CERS▲ +5.7%on this news
Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2024 Product Revenue and Provides Business Update
Cerus Corporation announced preliminary product revenues for 2024, totaling $180.3 million, representing a 15% increase over 2023 results. The company also projected 2025 product revenues between $194 and $200 million, reflecting ongoing growth driven by its INTERCEPT platelet franchise. While optimism surrounds the revenue progression, challenges such as market acceptance and reliance on external factors persist. Complete financial results for 2024 will be disclosed later this quarter.
Read more →CERSCerus Corporation Announces Third Quarter 2024 Financial Results Third Quarter and First Nine-Month Product Revenue Increased 16% and 18%, respectively from Prior Year Periods Raising Full-Year 2024 Total Product Revenue
Cerus Corporation announced its financial results for Q3 2024, showing a significant increase in product revenue of 16% compared to the previous year. The company has raised its full-year revenue guidance based on strong performance and growth expectations. Key highlights include a new six-year contract with BARDA valued at up to $248 million and continued developments in the INTERCEPT product pipeline, despite a decline in government contract revenues. The company's net loss decreased significantly, with positive adjusted EBITDA reported for the quarter.
Read more →CERSCerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe Company to Host Conference Call and Webcast on Wednesday
Cerus Corporation announced updates on its INTERCEPT red blood cell programs, highlighting a new $248 million contract with BARDA to support development efforts in the U.S. The company reported positive results from the ReCePI Phase 3 trial and is actively enrolling patients in the RedeS trial. However, they faced setbacks in Europe as their CE Mark application was not approved due to insufficient data regarding the product's impurity profile. Cerus remains optimistic about addressing these issues in future submissions.
Read more →About Cerus Corporation
Headquarters1220 CONCORD AVENUE, CONCORD, CA, 94520
BIOPHARMAWATCH ELITE PLUS
Trade the next CERS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime